The Role of p53 and MDM2 in Head and Neck Cancer.

Posted on 17 dicembre 2014

The Role of p53 and MDM2 in Head and Neck Cancer.

Denaro N, Lo Nigro C, Natoli G, Russi EG, Adamo V, Merlano MC.

ISRN Otolaryngol. 2011 Dec 7;2011:931813. doi: 10.5402/2011/931813. Print 2011.

Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.

Posted on 17 dicembre 2014

Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines. Guérin O, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC, Formento P, Lattanzio L, Maffi M, Tonissi F, Ortholan C, Pagès G, Fischel JL, Lo Nigro C, Merlano M, Milano G. Urol Oncol. 2013 Nov;31(8):1567-75. doi: 10.1016/j.urolonc.2012.03.003. Epub 2012 May […]

Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.

Posted on 17 dicembre 2014

Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.

Monteverde M, Tonissi F, Fischel JL, Etienne-Grimaldi MC, Milano G, Merlano M, Lo Nigro C.

Urol Oncol. 2013 Aug;31(6):776-86. doi: 10.1016/j.urolonc.2011.03.018. Epub 2011 Jul 27.

Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas.

Posted on 17 dicembre 2014

Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas.

Palmieri C, Rudraraju B, Monteverde M, Lattanzio L, Gojis O, Brizio R, Garrone O, Merlano M, Syed N, Lo Nigro C, Crook T.

Br J Cancer. 2012 Jul 10;107(2):375-81. doi: 10.1038/bjc.2012.231. Epub 2012 May 29.

High frequency of complex TP53 mutations in CNS metastases from breast cancer.

Posted on 17 dicembre 2014

High frequency of complex TP53 mutations in CNS metastases from breast cancer.

Lo Nigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, Quinlan PR, Syed N, Purdie CA, Thompson A, Palmieri C, Crook T.

Br J Cancer. 2012 Jan 17;106(2):397-404. doi: 10.1038/bjc.2011.464. Epub 2011 Dec 20.

Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis.

Posted on 17 dicembre 2014

Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis.

Garrone O, Crosetto N, Lo Nigro C, Catzeddu T, Vivenza D, Monteverde M, Merlano M, Feola M.

Cardiovasc Toxicol. 2012 Jun;12(2):135-42. doi: 10.1007/s12012-011-9149-4.

NT5E CpG island methylation is a favourable breast cancer biomarker

Posted on 17 dicembre 2014

NT5E CpG island methylation is a favourable breast cancer biomarker. Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T. Br J Cancer. 2012 […]

Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer

Posted on 17 dicembre 2014

Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer.

Merlano MC, Monteverde M, Colantonio I, Denaro N, Lo Nigro C, Natoli G, Giurlanda F, Numico G, Russi E.

Oral Oncol. 2012 Oct;48(10):1051-7. doi: 10.1016/j.oraloncology.2012.05.001. Epub 2012 Jun 2.

NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity

Posted on 17 dicembre 2014

NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, Harwood C, Syed N, Szlosarek P, Briasoulis E, McHugh A, Thompson A, Evans A, Leigh I, Fleming C, Inman GJ, Hatzimichael […]

Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications.

Posted on 17 dicembre 2014

Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications.

Hatzimichael E, Dasoula A, Kounnis V, Benetatos L, Lo Nigro C, Lattanzio L, Papoudou-Bai A, Dranitsaris G, Briasoulis E, Crook T.

Leuk Lymphoma. 2012 Sep;53(9):1709-13. doi: 10.3109/10428194.2012.661854. Epub 2012 Mar 13.